Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Maxygen and Roche Agree to Develop Factor VIIa Product
 

Pharmaceutical companies Maxygen and Roche have agreed to collaborate on the research, development and marketing of a new recombinant factor VIIa product. Factor VIIa is a protein integral to the blood coagulation process. The product could be used for the treatment of intra-cerebral hemorrhage (ICH), uncontrolled, trauma-induced bleeding and other indications. Under the agreement Maxygen, which is based in Redwood City, CA, will lead early stage clinical development and Roche, headquartered in Grenzacherstrasse, Switzerland, will lead the later stage. Roche retains exclusive rights to commercialize factor VIIa worldwide for acute indications, while Maxygen has the option to co-fund marketing activities in the U.S. In addition, Maxygen holds all rights to develop and commercialize recombinant factor VIIa product for the treatment of hemophilia.

The only recombinant factor VIIa product currently available is NovoSeven®, manufactured by Denmark-based Novo Nordisk. NovoSeven® is indicated for the treatment of hemophilia A and B patients with inhibitors to factor VIII and IX, and for bleeding episodes in patients with factor VII deficiency.

Source: PR Newswire and World Market Analysis, December 15, 2005

 

This section of our Web site is sponsored by: